Biotech Values

[DewDiligence]

ENTA/ABBV—As previously noted (#msg-91871095), the data to be presented at AASLD are not the data that matter for the global phase-3 program enumerated in #msg-92025068; rather, the data to be presented at AASLD are from ancillary phase-2 trials, including some new analysis of the SVR4-SVR12 concordance in the AVIATOR study, where the main data were presented at AASLD 2012 (#msg-80736847).

Hence, although the ABBV/ENTA data presented at 2013 AALSD will be worth examining, they won’t be market-moving. For that, investors have to wait for the companies to issue PRs on one or more of the phase-3 trials enumerated in #msg-92025068.

Note re study names: PEARL-1 is a phase-2 trial (data will be presented at AASLD), while PEARL-2, PEARL-3, and PEARL-4 are phase-3 trials (data will not be presented at AASLD).